Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today presented top-line data from the Phase 1/2 study of IONIS-HTTRx (RG6042) in people with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's DiseaseApril 24, 2018 12:15 PM Ionis Pharmaceuticals (IONS) PT Lowered to $74 at BMO CapitalApril 24, 2018 12:04 PM Biogen (BIIB) Reports New SPINRAZA (nusinersen) Data at AAN MeetingsApril 23, 2018 7:33 AM SAGE Therapeutics (SAGE) Defended at Raymond James, Says Selloff is Overreaction April 20, 2018 12:05 PM Ionis Pharmaceuticals (IONS) PT Raised to $75 at BMO Capital on Expanded Biogen DealApril 20, 2018 9:51 AM Biogen (BIIB) Reports $1B Payment to Ionis Pharma (IONS) for Expanded Collaboration on Neurological Diseases Drug DevelopmentApril 20, 2018 6:37 AM